ERX-315 Sensitizes Liver Cancer to PARP Inhibitors

San Antonio, TX – October 15, 2026Adriana Baker, a MD PhD candidate in the laboratory of EtiraRx founder Dr. Ratna Vadlamudi at UT Health San Antonio, presented exciting new findings at the 2026 San Antonio Liver Cancer Symposium, held…

ERX-208 Disrupts DNA Repair

San Antonio, TX – October 12, 2026We are pleased to share our new paper in Cancer Research Communications, showing that ERX-208, Etira’s LIPA-targeting compound, disrupts DNA repair in ovarian cancer cells by inducing sustained endoplasmic…

One Year on ERX-315

Dallas, Texas — September 7, 2026 Etira today announced that a patient enrolled in its ongoing Phase 1 clinical trial of ERX-315 (NCT06533332) has now remained on treatment for more than one year. The patient entered the ERX-315-101 study…

ERX research wins AACR award

San Diego, CA - April 20, 2026. Durga Paneerdoss, an undergraduate working in the laboratory of EtiraRx founder Ratna Vadlamudi received the Third Place Prize in the Margaret Foti Foundation Undergraduate Student Prize competition at the AACR…

Etira chosen for Mass Challenge!

Dallas, TX - April 14, 2026 We are pleased to announce that EtiraRx has been selected for the 2025 MassChallenge U.S. Early Stage Healthcare Cohort — a highly selective, zero-equity accelerator! This puts us alongside a global network of…

ERX-41 active in aggressive Breast Cancer

San Antonio, TX - March 23, 2026.We are pleased to present our new open-access paper in Biomolecules (link here).Our paper shows activity of ERX-41 in Inflammatory breast cancer (IBC), a rare (2–4%) extremely aggressive subset of breast…

Optimization of LIPA targeting in Ovarian Cancer

San Antonio TX, February 06, 2026Introducing ERX-208 - our supercharged ERX-41 analog for ovarian cancer!Publication in Oncogene shows the same powerful MOA of inducing uncompensated ER stress, but ERX-208 delivers dramatically higher…

Etira Board Member recognized in 2026 King’s New Year Honors

Congratulations to Dr Annalisa Jenkins OBE, a member of Etira’s Board of Directors, who has been appointed an Officer of the Order of the British Empire (OBE) in The King’s New Year Honours for her contributions to the life sciences.

Etira Founder’s Scientific Journey Highlighted

San Antonio, TX – November 18, 2025. Etira Founder Professor Ratna Vadlamudi delivered a compelling, deeply personal narrative as the featured speaker at the Health Cell State of the Industry event at the Tobin Center in San Antonio.

Etira CEO Featured In Clinical Leader for R&D Efficiency

Philadelphia, PA – July 16, 2025: In an article just published in Clinical Leader magazine entitled "How An Australia-First Strategy Cut 63% From Our R&D Spend", Etira CEO Russell Hayward explains how our strategic decision to conduct…